Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roblitinib - EverNov

Next Previous
Drug Profile

Roblitinib - EverNov

Alternative Names: EVER-4010001; FGF 401; NVP-FGF401

Latest Information Update: 22 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer EverNov; Novartis Oncology
  • Class Amides; Antineoplastics; Naphthyridines; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer; Solid tumours

Most Recent Events

  • 22 Aug 2023 Everest Medicines expects approval of NDA or BLA for Roblitinib in Liver cancer in 2025 and beyond (Everest Medicines pipeline, August 2023)
  • 22 Mar 2021 EverNov plans a phase II trial for Liver cancer in China in the second half of 2021
  • 09 Mar 2021 Phase-I/II development is ongoing in China, Italy, South Korea (PO) for Solid tumours and Liver cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top